机构:[a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China神经内科首都医科大学宣武医院[b]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China[c]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, P.R. China[d]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, P.R. China[e]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China[f]National Clinical Research Center for Geriatric Disorders, Beijing, P.R. China
Accumulating evidence has demonstrated that mitochondrial dysfunction is a prominent early event in the progression of Alzheimer's disease (AD). Whether protecting mitochondrial function can reduce amyloid-beta oligomer (A beta O)-induced neurotoxicity in PS1(V97L) transgenic mice remains unknown. In this study, we examined the possible protective effects of honokiol (HKL) on mitochondrial dysfunction induced by A beta Os in neurons, and cognitive function in AD PS1(V97L)transgenic mice. We determined that HKL increased mitochondrial sirtuin 3 (SIRT3) expression levels and activity, which in turn markedly improved ATP production and weakened mitochondrial reactive oxygen species production. We demonstrated that the enhanced energy metabolism and attenuated oxidative stress of HKL restores A beta O-mediated mitochondrial dysfunction in vitro and in vivo. Consequently, memory deficits in the PS1(V97L) transgenic mice were rescued by HKL in the early stages. These results suggest that HKL has therapeutic potential for delaying the onset of AD symptoms by alleviating mitochondrial impairment and increasing hyperactivation of SIRT3 in the pathogenesis of preclinical AD.
基金:
This study was supported by the Key Project
of the National Natural Science Foundation of
China (81530036); the National Key Scientific
Instrument and Equipment Development Project
(31627803); Mission Program of Beijing Municipal Administration of Hospitals (SML20150801); Beijing
Scholars Program; Beijing Brain Initiative from
Beijing Municipal Science & Technology Commission
(Z161100000216137); CHINA-CANADA
Joint Initiative on Alzheimer’s Disease and Related
Disorders (81261120571) and Beijing Municipal
Commission of Health and Family Planning
(PXM2017 026283 000002).